Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Colorcon
Express Scripts
Medtronic
Dow
Fuji
Citi
Merck
AstraZeneca
Novartis

Generated: January 22, 2018

DrugPatentWatch Database Preview

Bromocriptine mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for bromocriptine mesylate and what is the scope of bromocriptine mesylate patent protection?

Bromocriptine mesylate
is the generic ingredient in three branded drugs marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Us Pharms Holdings I, Paddock Llc, Sandoz Inc, and Veroscience, and is included in eight NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bromocriptine mesylate has twenty-one patent family members in twelve countries.

There are nine drug master file entries for bromocriptine mesylate. Thirteen suppliers are listed for this compound.
Summary for bromocriptine mesylate
Pharmacology for bromocriptine mesylate
Ingredient-typeErgolines
Drug ClassErgot Derivative
Medical Subject Heading (MeSH) Categories for bromocriptine mesylate

US Patents and Regulatory Information for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mylan BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 076962-001 Sep 24, 2004 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Zydus Pharms Usa Inc BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 078899-001 Jul 30, 2008 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lek Pharm BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 075100-001 Dec 10, 1998 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Subscribe ➤ Subscribe
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for bromocriptine mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,700,555 Bromocriptine formulations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for bromocriptine mesylate

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
Mallinckrodt
Citi
Harvard Business School
Dow
US Army
Novartis
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot